Skip to main content Skip to search Skip to main navigation
News: Europe

Now published: EN 17141:2020 Cleanrooms and associated controlled environments – biocontamination control

The new European standard EN 17141:2020 has been issued on 12 August 2020 and will replace the DIN EN ISO 14698 (Parts 1 and 2) of the year 2003, which no longer reflects the state of the art.

EN 17141 is based on a quality risk management approach and defines the modern principles and basic methodology of an operational system for the control of biocontamination in cleanrooms and all associated controlled areas. It specifies methods for a consistent assessment of the risk areas to be monitored and the application of control measures according to the existing level of risk. In addition, new ways of evaluating and verifying microbiological sampling equipment are identified. Users will be supported in standardizing their monitoring in order to compare the results from one facility with those of another.The practical annexes of the document containing checklists, flowcharts, tables on cleanliness levels and application examples, are to be highlighted.

EN 1741:2020 is addressed to everyone involved in contamination control, from engineering support to quality assurance. The standard is proposed  for inclusion in the group of ISO 14644 by the European work on biocontamination control (CEN/TC 243).


Source:

BSI

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: ICH

ICH: Adoption of the ICH Q1 Stability Guideline

The Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) met on 17-18 November 2026 in Prague, Czechia for its biannual meeting. ICH announced, among other things, adoption of ICH Q1: Stability Testing of Drug Substances and Drug Products as a final harmonised guideline.
Read more
FDA Expands Sampling and Testing of Marketed Medicines

FDA Expands Sampling and Testing of Marketed Medicines

Through its Enhanced Approach for Sampling and Testing (EAST) program, the US Food and Drug Administration combines rapid analytical techniques with established testing methods. The agency aims to test more medicines from US and overseas manufacturers, detect potential quality issues earlier, and use the findings to inform risk-based inspection planning.
Read more
FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
Previous
Next